Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
Start Time: 07:00 End Time: 08:45 Roche Holding AG (RHHBY) Q2 2020 Earnings Conference Call July 23, 2020, 07:00 AM ET Company Participants Severin Schwan - CEO Alan Hippe - Chief Financial and IT Officer Bill Anderson - CEO, Roche Pharmaceuticals Thomas Schinecker - CEO, R...
The following slide deck was published by Roche Holding AG in conjunction with their 2020 Q2 earnings Read more ...
Roche Holding ( OTCQX:RHHBY ) H1 results (CHF): More news on: Roche Holding AG, Healthcare stocks news, Earnings news and commentary, Read more ...
Roche Holding ( OTCQX:RHHBY ) : 1H Non-GAAP EPS of CHF10.44 beats by CHF0.04 ; GAAP EPS of CHF9.32. More news on: Roche Holding AG, Earnings news and commentary, Healthcare stocks news, Read more ...
Following up on its first announcement two months ago, Roche ( OTCQX:RHHBY +0.3% ) reports detailed results from its successful Phase 3 clinical trial, ARCHWAY , evaluating its Port Delivery System (PDS) with ranibizumab in patients with neovascular age-related macular degeneration (w...
In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable benefit-risk profile PDS is a permanent refillable eye implant that continuously delive...
Quick Take iTeos Therapeutics ( ITOS ) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a range of treatments for various cancers, including solid tumors. ITOS is pursuing treatments for...
NetworkNewsWire Editorial Coverage : Effective pandemic response relies first and foremost on fast and accurate testing to buy time and save lives while therapeutics and vaccines are developed. Coronavirus cases continued to surge in the US this month, showing no signs of slowing since lock...
Exelixis (NASDAQ: EXEL ) has initiated CONTACT-03 , a global phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) in patients with inoperable, locally advanced or metastatic renal cell carcinoma (RCC) who progressed during or following trea...
Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks – – The twice-yearly, 10-minute SC injection has th...
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination ...